IL2RA and type 1 diabetes mellitus: A clinical trial demonstrated that it is particularly difficult to design an aldesleukin dose regimen in patients with T1D to obtain a sustained expansion of circulating CD4+CD25+CD127lo Tregs without fueling the expansion of disease-promoting Teffs, NK cells, and eosinophils (61).